Karyopharm Therapeutics (KPTI) Competitors

Gossamer Bio (NASDAQ:GOSS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Do institutionals & insiders have more ownership in GOSS or KPTI?

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts recommend GOSS or KPTI?

Gossamer Bio currently has a consensus price target of $7.50, indicating a potential upside of 607.55%. Karyopharm Therapeutics has a consensus price target of $57.50, indicating a potential upside of 750.59%. Given Karyopharm Therapeutics' higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Karyopharm Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor GOSS or KPTI?

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.36 beat Karyopharm Therapeutics' score of 0.20 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer GOSS or KPTI?

Karyopharm Therapeutics received 386 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 66.81% of users gave Gossamer Bio an outperform vote.

Company	Underperform	Outperform
Gossamer Bio	Outperform Votes 155 66.81%	Underperform Votes 77 33.19%
Karyopharm Therapeutics	Outperform Votes 541 72.42%	Underperform Votes 206 27.58%

Which has more risk and volatility, GOSS or KPTI?

Gossamer Bio has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Which has better earnings and valuation, GOSS or KPTI?

Karyopharm Therapeutics has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$114.70M	2.10	-$179.82M	-$0.26	-4.08
Karyopharm Therapeutics	$145.24M	0.40	-$143.10M	-$15.29	-0.44

Is GOSS or KPTI more profitable?

Gossamer Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	N/A	-127.28%	-22.12%
Karyopharm Therapeutics	-52.62%	N/A	-39.58%

Summary

Gossamer Bio beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.